We can do all of this work on trying to make sure that we approve biosimilars, but if they're not actually getting prescribed, if we aren't giving FDA the resources to make the case that they should be prescribed, we're going to be spending billions and billions of additional dollars that we don't need to simply because we're continuing to funnel money to the makers of the original product who are in competition with the maker of the biosimilar.
Editor's note · Context
Senator Murphy warns about financial implications if biosimilars are not prescribed.
Share
More from Chris Murphy
We write for a second time regarding the unconstitutional and illegal attempt to transform the United States Postal Service into an election administration agency controlled by the White House and President Trump.
Americans deserve answers on how the administration has decided to spend their taxpayer dollars and assume new national security risks with the VC-25B Bridge aircraft and the rushed retrofit program contracted to L3Harris – all in service…
This long-overdue step will save millions in taxpayer dollars, cut red tape, and support economic development by allowing better collaboration between the Coast Guard and its surrounding communities – in places like New London…





